Next Article in Journal
The Long Intron 1 of Growth Hormone Gene from Reeves’ Turtle (Chinemys reevesii) Correlates with Negatively Regulated GH Expression in Four Cell Lines
Next Article in Special Issue
The Development of Sugar-Based Anti-Melanogenic Agents
Previous Article in Journal
Redox Proteomic Profiling of Specifically Carbonylated Proteins in the Serum of Triple Transgenic Alzheimer’s Disease Mice
Previous Article in Special Issue
Bird Integumentary Melanins: Biosynthesis, Forms, Function and Evolution

A Novel Role of Serotonin Receptor 2B Agonist as an Anti-Melanogenesis Agent

Department of Genetic Engineering, Graduate School of Biotechnology, Kyung Hee University, Yongin 446-701, Korea
Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong Songpa-gu, Seoul 138-736, Korea
Authors to whom correspondence should be addressed.
Academic Editor: Manickam Sugumaran
Int. J. Mol. Sci. 2016, 17(4), 546;
Received: 29 February 2016 / Revised: 6 April 2016 / Accepted: 7 April 2016 / Published: 12 April 2016
(This article belongs to the Special Issue Biochemistry and Mechanisms of Melanogenesis)
BW723C86, a serotonin receptor 2B agonist, has been investigated as a potential therapeutic for various conditions such as anxiety, hyperphagia and hypertension. However, the functional role of BW723C86 against melanogenesis remains unclear. In this study, we investigate the effect of serotonin receptor 2B (5-HTR2B) agonist on melanogenesis and elucidate the mechanism involved. BW723C86 reduced melanin synthesis and intracellular tyrosinase activity in melan-A cells and normal human melanocytes. The expression of melanogenesis-related proteins (tyrosinase, TRP-1 and TRP-2) and microphthalmia-associated transcription factor (MITF) in melan-A cells decreased after BW723C86 treatment. The promoter activity of MITF was also reduced by BW723C86 treatment. The reduced level of MITF was associated with inhibition of protein kinase A (PKA) and cAMP response element-binding protein (CREB) activation by BW723C86 treatment. These results suggest that the serotonin agonist BW723C86 could be a potential therapeutic agent for skin hyperpigmentation disorders. View Full-Text
Keywords: BW723C86; melanogenesis; PKA; CREB; MITF BW723C86; melanogenesis; PKA; CREB; MITF
Show Figures

Graphical abstract

MDPI and ACS Style

Oh, E.J.; Park, J.I.; Lee, J.E.; Myung, C.H.; Kim, S.Y.; Chang, S.E.; Hwang, J.S. A Novel Role of Serotonin Receptor 2B Agonist as an Anti-Melanogenesis Agent. Int. J. Mol. Sci. 2016, 17, 546.

AMA Style

Oh EJ, Park JI, Lee JE, Myung CH, Kim SY, Chang SE, Hwang JS. A Novel Role of Serotonin Receptor 2B Agonist as an Anti-Melanogenesis Agent. International Journal of Molecular Sciences. 2016; 17(4):546.

Chicago/Turabian Style

Oh, Eun Ju, Jong Il Park, Ji Eun Lee, Cheol Hwan Myung, Su Yeon Kim, Sung Eun Chang, and Jae Sung Hwang. 2016. "A Novel Role of Serotonin Receptor 2B Agonist as an Anti-Melanogenesis Agent" International Journal of Molecular Sciences 17, no. 4: 546.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop